title: [Therapy education for patients receiving oral anti-coagulants vitamin K antagonists].
abstract: The vitamin K antagonists (VKA) remain to this day the only oral form of therapeutic anticoagulation. Approximately 1% of the French population, mainly elderly, is treated with these anticoagulants. Oral anticoagulants have significant risks of iatrogenic complications; indeed they are the leading cause of such drug-induced complications, predominantly hemorrhages. AFSSAPS (French Drug and Medical Products Agency) clinical practice recommendations, repeatedly disseminated, emphasize the education of patients receiving VKAs. Managing oral anticoagulant treatment is challenging, with a significant risk of under- or overdosing and consequently, thrombosis or hemorrhage. The therapeutic window is narrow, multiple drug-interactions are possible, and the specific dose required for a particular individual to achieve appropriate International Normalized Ratio (INR) levels is unpredictable. The literature contains few randomized controlled trials about the efficacy of education for patients treated with oral anticoagulants. These education programs are not standardized and are therefore varied and difficult to compare. Nevertheless, studies demonstrate the importance of patient education programs in reducing the risk of hemorrhage and achieving better treatment stability. The Grenoble region hospital-community network for vascular diseases (GRANTED) has developed an education program for these patients, consisting of individual sessions for the patient and/or a friend or family member (either at a health care facility or at the patient's home), telephone support and group sessions, and using educational tools and supports. There is also a link with the general practitioner who receives a report. This approach makes it possible to adapt the educational message to individual patients and their daily lives, as well as directly involving them in the management of their treatment.
authors.affiliation: Réseau ville-hôpital Granted, Grenoble, F-38400 ST Martin D'Hères, France.
authors.forename: Bernadette
authors.initials: B
authors.lastname: Satger
authors.forename: Sophie
authors.initials: S
authors.lastname: Blaise
authors.forename: Michèle
authors.initials: M
authors.lastname: Fontaine
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Yver
authors.forename: Benoît
authors.initials: B
authors.lastname: Allenet
authors.forename: Magali
authors.initials: M
authors.lastname: Baudrant
authors.forename: Gilles
authors.initials: G
authors.lastname: Pernod
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Bosson
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D003299:Cooperative Behavior; D004305:Dose-Response Relationship, Drug; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D033183:Interdisciplinary Communication; D055118:Medication Adherence / Q000523:psychology; D009723:Nurse-Patient Relations; D010348:Patient Care Team; D010353:Patient Education as Topic / Q000379:methods*; D010817:Physician-Patient Relations; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012944:Social Support; D013927:Thrombosis / Q000139:chemically induced; D016896:Treatment Outcome; D014812:Vitamin K / Q000037:antagonists & inhibitors*
chemical_list: D000925:Anticoagulants; D014812:Vitamin K